EGFR p.V774M/p.L833V compound mutations in lung adenocarcinoma responded well to almonertinib: a case report

• Published in: Frontiers in oncology 2023, Vol.13, p.1159308-1159308
• Main Authors: Pan, Hai, Zhang, Linlin, Meng, Fanlu, Guan, Shasha, Zhong, Diansheng
• Format: Report
• Language: English
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2023.1159308

BackgroundThere are about 10-15% of uncommon EGFR mutations found in NSCLC patients, and their sensitivity to EGFR TKIs still lack sufficient clinical evidence, especially for rare compound mutations. Almonertinib is the third generation of EGFR-TKI that has demonstrated excellent efficacy in classical mutations, however, effects in rare mutations have also been rarely reported. Case presentationIn this case report, we present a patient with advanced lung adenocarcinoma with a rare EGFR p.V774M/p.L833V compound mutations, who achieved long-lasting and stable disease control after first-line Almonertinib targeted therapy. This case report could provide more information for therapeutic strategy selecting of NSCLC patients harboring rare EGFR mutations. ConclusionWe report for the first time the long-lasting and stable disease control with Almonertinib for EGFR p.V774M/p.L833V compound mutations treatment, hoping to provide more clinical case references for the treatment of rare compound mutations.